Parag Goyal, MD

Highlights

1
European heart journal · 2022
MKMichael Kim PGParag Goyal SMStephen McCullough JWJim W. Cheung+3 more →HKHooman Kamel
PMID: 35764099PMCID: PMC9890619DOIFirst author56 citations
2
Journal of the American Heart Association · 2020
MRMadeline R. Sterling LPLaura Pinheiro MMMonika M Safford EPErica Phillips PGParag Goyal
PMID: 32316807PMCID: PMC7428585DOISenior author85 citations
3
Circulation. Heart failure · 2020
MMMonika M Safford MSMark Steven Lachs PGParag Goyal
PMID: 33045844PMCID: PMC8819498DOISenior author167 citations

Publications

325

Funding

31 View NIH portfolio on RePORTER ↗

Active

16 grants

PI
DEPRESCRIBE-HFPEF
National Institute on Aging · 2025–2029
R01AG091005-02
Sub-PI
N-of-1 Trials to Promote Patient-Centered β-blocker Titration in Heart Failure with Reduced Ejection Fraction
National Institute on Aging · 2025–2029 · via Brigham and Women's Hospital
P30AG064199-07
Sub-PI
Medication Effects in Post-Acute Heart Failure Care
National Institute on Aging · 2024–2029 · via Brown University
R01AG088522-03
Co-I
Structural Racism and Cardiovascular Outcomes Among Cancer Survivors
National Cancer Institute · 2024–2029
R37CA288492-01
PI
Preventing Myocardial Events of Aging: A PREVENTABLE Ancillary Study
National Institute on Aging · 2024–2028
R01AG085420-03
Co-I
I-TRANSFER-HF: Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe: A Type 1 Hybrid Effectiveness Implementation Trial
National Heart, Lung, and Blood Institute · 2023–2028
R01HL169312-01
MPI
Pragmatic Evaluation Of Events And Benefits Of Lipid-Lowering In Older Adults (Preventable)
National Institute on Aging · 2020–2027 · via Duke University
U19AG065188-05
Sub-PI
Coronary Artery Calcium in the PRagmatic EValuation of evENTs And Benefits of Lipid lowering in the Elderly: CAC PREVENTABLE Ancillary Study
National Heart, Lung, and Blood Institute · 2023–2027 · via Duke University
R01HL155396-04
Sub-PI
Physical Rehabilitation for Older Patients with Acute HFpEF-The REHAB-HFpEF Trial
National Institute on Aging · 2022–2027 · via Wake Forest University Health Sciences· 2 renewals
R01AG078153-04
Co-I
REasons for Geographic And Racial Differences in Stroke-Myocardial Infarction-4 (REGARDS-MI-4)
National Heart, Lung, and Blood Institute · 2022–2027
R01HL165452-01
Co-I
Cardiac Magnetic Resonance for Tissue Characterization Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors
National Heart, Lung, and Blood Institute · 2021–2027
R01HL159055-01
Co-I
Heart Failure Endotypes from Ethical, Multi-Modal AI driven and Molecular/Phenotypic Data Integration Enabled Discovery
Office of the Director, NIH · 2025–2026 · via Northwestern University
OT2OD038083-01
Sub-PI
Improve the Meaning of Patient Reported Outcomes to Evaluate Effectiveness for Cardiac Care" (IMPROVE-Cardiac Care)
National Heart, Lung, and Blood Institute · 2022–2026 · via Columbia University
R01HL161458-04
MPI
Advancing the Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention
National Institute on Aging · 2023–2026
R21AG077092-02
PI
A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF): A Prototype for Older Adults with Multimorbidity and Polypharmacy
National Institute on Aging · 2020–2025Career
5 K76A G064428-04
PI
A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF): A Prototype for Older Adults with Multimorbidity and Polypharmacy
NIA · 2020–2025 · via NIH RePORTER
K76AG064428-05

Completed grants (15)

Sub-PI
N-of-1 Trials to Promote Deprescribing in Older Adults with Transthyretin Cardiac Amyloidosis
National Institute on Aging · 2023–2025 · via Northern California Institute for Research & Education
R24AG064025-05
Co-I
Using Mobile Integrated Health and Telehealth to Support Transitions of Care among Heart Failure Patients
Patient-Centered Outcomes Research Institute · 2020–2024
IHS-2019C2-17373
PI
Cardiovascular Disease and Successful Aging
American Heart Association · 2020–2023
AHA 775419-03
KP
The Impact of Social Determinants of Health on Quality of Life; Program: Research Supplement to Promote Diversity in Science (1 Year); Application ID: 966638
American Heart Association · 2022–2023
AHA 223169-01
Co-I
Should we return patient reported outcomes to human subjects participants?-exploring ethical obligations
National Institute of Nursing Research · 2020–2022
R00NR016275-05S1
Sub-PI
TRANSFORM-HF (ToRsemide compArisoN with furoSemide FOR Management of Heart Failure) Study
National Heart, Lung, and Blood Institute · 2017–2022 · via Yale University· 2 renewals
U01HL125511-02
PI
"Safety of Neurohormonal Antagonist Initiation Among Older Adults with Heart Failure Following a Heart Failure Hospitalization"
American Heart Association · 2018–2021
18IPA34170185
Co-I
Deep Learning for Peripheral Edema Phenotyping
Heart Failure Society of America · 2018–2020
HFSA 191277-01
Sub-PI
Impact of In-hospital Kidney Function, Electrolytes, and Vital Signs on Neurohormonal Antagonist Prescriptions Following a Heart Failure Hospitalization
Amgen Inc. · 2019–2020 · via The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
UAB 200726-01
Sub-PI
Neurohormonal Antagonist Intolerance and Dose Reductions Following Heart Failure Hospitalizations
Amgen Inc. · 2019–2020 · via The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
UAB 200721-01
PI
Impact of Polypharmacy on Rehospitalization in Older Adults with Heart Failure
National Institute on Aging · 2017–2020
R03AG056446-02
Sub-PI
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)
National Heart, Lung, and Blood Institute · 2017–2019 · via The Brigham & Women's Hospital INC
U01HL130163-04
Sub-PI
Outcomes Research in Heart Failure Among Americans (Patterns of Comorbidity among Medicare Beneficiaries Hospitalized for Heart Failure with Preserved Ejection Fraction)
Amgen Inc. · 2019–2019 · via The Board of Trustees of the University of Alabama for the University of Alabama at BirminghamContract
UAB 190144-01
Sub-PI
ToRsemide compArisoN with furoSemide FOR Management of Heart Failure (TRANSFORM-HF)
National Heart, Lung, and Blood Institute · 2018–2018 · via Duke University
DU 190291-01
Sub-PI
Delivery System Reform Incentive Payment (DSRIP) - Hospital Readmissions
New York State Department of Health · 2017–2018 · via New York Presbyterian Hospital
NYPH 183615-01

Clinical research

37

Active

17 studies

PI
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction
PHASE3 · Tenax Therapeutics Inc. · OPEN TO ACCRUAL (as of 2026)
Pulmonary Hypertension Associated With HFpEF
NCT07288398
PI
N-of-1 Trials to Promote Patient-Centered Beta-Blocker Titration in Heart Failure With Reduced Ejection Fraction
NA · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
Heart Failure; Beta-blocker; Older Adults
NCT07489352
PI
CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
PHASE3 · Novo Nordisk Pharmaceuticals, Inc. · OPEN TO ACCRUAL (as of 2026)
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
NCT07207811
PI
Differential Approaches to Terminal Disease between Cardiologist and Oncologists
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
PI
Determining Evidence in a Placebo-Controlled, Randomized Experiment Studying Continuation vs. Removal of Inessential Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
PHASE4 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
Heart Failure; HFpEF; HFpEF - Heart Failure With Preserved Ejection Fraction
NCT07298993
PI
Pilot Study of Acceptability and Feasibility of StudyU for N-of-1 Trials
PHASE4 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
HFrEF - Heart Failure With Reduced Ejection Fraction; Heart Failure; Heart Failure, Systolic; Heart Diseases
NCT07252310
PI
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
PHASE3 · Alnylam Pharmaceuticals, Inc. · OPEN TO ACCRUAL (as of 2025)
Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903
PI
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction: Randomized Controlled Feasibility Trial - The Rebalance HF Study
NA · Axon Therapies, Inc · OPEN TO ACCRUAL (as of 2025)
Heart Failure With Preserved Ejection Fraction (HFpEF
NCT04592445
PI
Impact of Polypharmacy on Rehospitalization in Older Adults with Heart Failure
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
PI
Preventing Myocardial Events of Aging: A PREVENTABLE Ancillary Study
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
PI
An Open-Label Extension Study to Assess the Long-Term Safety of Eplontersen (ION-682884) in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
PHASE3 · Ionis Pharmaceuticals, Inc. · OPEN TO ACCRUAL (as of 2024)
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
NCT05667493
PI
Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
PHASE3 · Novo Nordisk Pharmaceuticals, Inc. · OPEN TO ACCRUAL (as of 2023)
Heart Failure
NCT05636176
PI
Improve the Meaning of Patient-Reported Outcomes to Evaluate Effectiveness for Cardiac Care (IMPROVE-Cardiac Care)
Columbia University · OPEN TO ACCRUAL (as of 2023)
PI
A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication Optimization
PHASE4 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2023)
Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure; Heart Diseases
NCT05585125
PI
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection
NA · Wake Forest University Health Sciences · OPEN TO ACCRUAL (as of 2023)
Heart Failure With Preserved Ejection Fraction
NCT05525663
PI
Participant Qualitative Interviews about Reason for Declining Participation in Heart Failure Deprescribing Trial
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2021)
PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)
PHASE4 · Duke University · OPEN TO ACCRUAL (as of 2020)
Cognitive Impairment, Mild; Dementia; Cardiovascular Diseases
NCT04262206

Completed & closed trials (20)

PI
A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
PHASE2 · Bristol-Myers Squibb Company · IRB STUDY CLOSURE (as of 2026)
Heart Failure
NCT06122779
PI
N-of-1 Trials to Promote Deprescribing in Older Adults With Transthyretin Cardiac Amyloidosis
PHASE4 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2026)
Cardiac Amyloidosis; Heart Diseases; TTR Cardiac Amyloidosis
NCT05019027
PI
A Pilot Hybrid Effectiveness-Implementation Trial for the Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention
NA · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2026)
HFpEF - Heart Failure With Preserved Ejection Fraction
NCT06994325
PI
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
PHASE3 · Tenax Therapeutics Inc. · CLOSED TO ACCRUAL (as of 2026)
Pulmonary Hypertension
NCT05983250
PI
Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved Ejection Fraction (EF) Heart Failure (Protocol #2201)
NA · Corvia Medical, Inc. · CLOSED TO ACCRUAL (as of 2026)
Heart Failure; Heart Failure, Diastolic
NCT05425459
PI
Cardiac Amyloidosis Registry Study - A Multi-Center, Longitudinal, Observational Survey of Patients With Cardiac Amyloidosis
Cedars-Sinai Medical Center · IRB STUDY CLOSURE (as of 2025)
Amyloidosis, Immunoglobulin Light-chain
NCT05174338
PI
Physician Qualitative Interviews About Decision-Making in Heart Failure
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
PI
Feasibility of home-based, ambient passive sensor technology to provide early warning of health decompensation by detecting deviations in activities of daily living (ADLs) of elderly subjects with diagnosed chronic disease
Sensorum Health Inc. · IRB STUDY CLOSURE (as of 2025)
PI
Exploratory Phase 2A, Double-blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety, Tolerability, PD, and PK of HU6 for the Treatment of Subjects With Obese Heart Failure With Preserved Ejection Fraction (HFpEF)
PHASE2 · Rivus Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2024)
Heart Failure With Preserved Ejection Fraction
NCT05284617
PI
Successful Aging and Cardiovascular Disease
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
PI
Cardiovascular Risk in COVID-19 Survivors
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
PI
Weill Cornell COVID-19 Observational Research Cohort
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
PI
An Exploratory, Open-label, Proof-of-concept, Phase 2a Study of Mavacamten (MYK-461) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Biomarkers
PHASE2 · MyoKardia, Inc. · IRB STUDY CLOSURE (as of 2024)
Heart Failure With Preserved Ejection Fraction
NCT04766892
PI
Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction
PHASE3 · Novo Nordisk Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2023)
Obesity
NCT04788511
PI
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
PHASE3 · Ionis Pharmaceuticals, Inc. · CLOSED TO ACCRUAL (as of 2023)
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
NCT04136171
PI
A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication Optimization
PHASE4 · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure; Heart Diseases
NCT05585125
PI
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF
PHASE4 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)
Heart Failure; Heart Failure, Diastolic; Heart Failure With Preserved Ejection Fraction; Cardiac Failure; Heart Disease
NCT04757584
PI
An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
PHASE3 · AstraZeneca Pharmaceuticals LP · IRB STUDY CLOSURE (as of 2022)
Heart Failure With Preserved Ejection Fraction
NCT03619213
PI
Convalescent CoVID 19 Plasma in the Treatment of High Risk CoVID-19 Disease
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
PI
A Multi-center, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults with Severe COVID-19
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2021)

News mentions

5 View all WCM news ↗

Race Doesn't Impact Cardiovascular Risk Calculations
December 6, 2023
Removing race information from cardiovascular risk calculators—which predict the probability of developing heart disease—doesn’t affect patients’ risk scores, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Post-Operative Atrial Fibrillation Associated with Higher Risk for Heart Failure
June 29, 2022
A new onset of a rapid or irregular heartbeat that develops after surgery, often within a few days, is associated with an increased risk for hospitalization for heart failure among patients undergoing both cardiac and noncardiac surgery, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Record Number of Weill Cornell Faculty Win ASCI Young Physician-Scientist Awards
May 27, 2021
Eight Weill Cornell Medicine faculty members have received Young Physician-Scientist Awards from the American Society for Clinical Investigation (ASCI), the most awarded to any institution this year.
In Brief: Analysis of Risk Factors for COVID-19
July 23, 2020
Weill Cornell Medicine and NewYork-Presbyterian investigators examined patient data to determine how obesity and inflammatory bowel disease affect SARS-CoV-2 infection and the course of COVID-19.
In Brief: COVID-19 Clinical Characteristics
June 22, 2020
When COVID-19 first appeared in NYC hospitals, Weill Cornell Medicine and NewYork-Presbyterian physicians and scientists documented early observations of clinical and pathological characteristics in two publications.

Mentoring

4 All publications with mentees →

External relationships

Advisory/Scientific Board Member

Axon Therapies, Inc

Other

Alnylam Pharmaceuticals, Inc. · Bayer Healthcare Pharmaceuticals · Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · BridgeBio Pharma, Inc. · Pfizer, Inc. · Tenax Therapeutics Inc.